INTRACEREBROVENTRICULAR INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED STEM CELLS FOR THE TREATMENT OF ALZHEIMER’S DISEASE: EXPERIENCE WITH THE FIRST OF THREE 3-PATIENT COHORTS IN A “FIRST IN HUMAN” PHASE 1 FDA TRIAL

Authors
Category Primary study
Conference17th Clinical Trials on Alzheimer’s Disease
Year 2025
This article has no abstract
Epistemonikos ID: 299d98dc429f82ed7a3c0b3e8964f4cfbaf79b71
First added on: Sep 05, 2026